NeuroBo Pharmaceuticals(NRBO) - 2025 Q3 - Quarterly Report
2025-11-06 21:07
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 (Mark One) Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37809 METAVIA INC. (Exact name of Registrant as specified in its charter) Delaware 47-2389984 (State or othe ...
LAVA Therapeutics(LVTX) - 2025 Q3 - Quarterly Report
2025-11-06 21:07
Table of Contents OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition period from to Commission file number: 001-40241 LAVA Therapeutics N.V. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 (Exact Name of Registrant as Specified in Its Charter) The Netherlands (Stat ...
Gen Digital (GEN) - 2026 Q2 - Quarterly Results
2025-11-06 21:07
NEWS RELEASE CONTACTS Investor Contact Jason Starr Gen Gen Media Contact Audra Proctor IR@GenDigital.com Press@GenDigital.com Gen Extends Market Leadership with Record Results in Q2 FY26 Company Raises Outlook as Secure Financial Wellness Fuels Next Stage of Growth TEMPE, Ariz. & PRAGUE – November 6, 2025 – Gen Digital Inc. (NASDAQ: GEN), a global leader dedicated to powering Digital Freedom, released its results for its second quarter fiscal year 2026, which ended October 3, 2025. "Our record results demon ...
Processa Pharmaceuticals(PCSA) - 2025 Q3 - Quarterly Report
2025-11-06 21:07
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission File Number 001-39531 Processa Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 45-1539785 (S ...
DiamondRock Hospitality pany(DRH) - 2025 Q3 - Quarterly Results
2025-11-06 21:07
COMPANY CONTACTS Dori Kesten Capital Markets (617) 835-8366 DIAMONDROCK HOSPITALITY COMPANY REPORTS THIRD QUARTER 2025 RESULTS Raises Midpoint of 2025 Adjusted EBITDA and Adjusted FFO Guidance Repurchased 4.8 Million Common Shares Year To Date BETHESDA, Maryland, Thursday, November 6, 2025 – DiamondRock Hospitality Company (NYSE: DRH) (the "Company"), a lodging real estate investment trust that owns a portfolio of 36 premium hotels and resorts in the United States, today announced results of operations for ...
Affirm(AFRM) - 2026 Q1 - Quarterly Results
2025-11-06 21:07
affirm) First Fiscal Quarter 2026 Shareholder Letter a) ·1234 (0) Pay over time Pay in full <> Purchasing power > Plan a purchase Get your vintage deep cuts for as a low as 0% APR. Shop now → Fellow Affirm Shareholders, We delivered another set of stellar results to get fiscal 2026 started, in both growth and profitability rubrics. Gross Merchandise Volume Revenue Less Transaction ("GMV") Revenue Costs ("RLTC")1 +42% +34% +60% Operating Income Adjusted Operating Income1 Net Income As a percent of Revenue As ...
BlackLine(BL) - 2025 Q3 - Quarterly Results
2025-11-06 21:07
Third Quarter Key Metrics and Recent Business Highlights EXHIBIT 99.1 BlackLine Announces Third Quarter Financial Results LOS ANGELES, Nov. 06, 2025 (GLOBE NEWSWIRE) -- BlackLine, Inc. (Nasdaq: BL), today announced financial results for the third quarter ended September 30, 2025. "BlackLine's third-quarter results, with increasing revenue growth, solid margins, and strong free cash flow, demonstrate that our focus on improved execution is taking hold," said Owen Ryan, CEO of BlackLine. "The deliberate chang ...
Viatris(VTRS) - 2025 Q3 - Quarterly Report
2025-11-06 21:07
For the quarterly period ended September 30, 2025 OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to___________ Commission file number 001-39695 VIATRIS INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incor ...
AvePoint(AVPT) - 2025 Q3 - Quarterly Results
2025-11-06 21:07
AvePoint Announces Third Quarter 2025 Financial Results Third quarter SaaS revenue of $84.0 million, representing 38% year-over-year growth, 35% on a constant currency basis Third quarter Total revenue of $109.7 million, representing 24% year-over-year growth, 21% on a constant currency basis Total ARR of $390.0 million, representing 26% year-over-year growth JERSEY CITY, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- AvePoint (NASDAQ: AVPT, SGX: AVP), the global leader in data security, governance and resilience, ...
Fidus Investment (FDUS) - 2025 Q3 - Quarterly Results
2025-11-06 21:07
Exhibit 99.1 FIDUS INVESTMENT CORPORATION ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS Board of Directors Declared Total Dividends of $0.50 per Share for Fourth Quarter 2025 Base Dividend of $0.43 and Supplemental Dividend of $0.07 Per Share EVANSTON, Ill., November 6, 2025 – Fidus Investment Corporation (NASDAQ:FDUS) ("Fidus" or the "Company"), a provider of customized debt and equity financing solutions, primarily to lower middle-market companies based in the United States, today announced its financial ...